$TGTX - On our trading list. This has been a hot stock last few months with bullish momentum building. 2 Analysts raised their price targets on Friday morning.TG Therapeutics price target raised to $25 from $17 at B. Riley FBRB. Riley FBR analyst Mayank Mamtani raised his price target for TG Therapeutics to $25 from $17 after the company initiated a rolling new drug application for two hematologic malignancies after recently receiving guidance from the FDA that a single NDA for both indications would be acceptable to allow accelerated approval. The analyst continues to believe in "substantial equity upside," citing the de-risked nature of several clinical and regulatory catalysts through 2020. He reiterates a Buy rating on the shares.TG Therapeutics price target raised to $24 from $20 at H.C. WainwrightH.C. Wainwright analyst Edward White raised his price target for TG Therapeutics to $24 from $20 after the company initiated a rolling new drug application submission to the FDA for accelerated approval of umbralisib for the treatment of previously treated marginal zone lymphoma and follicular lymphoma. This news is positive considering the inclusion of follicular lymphoma should ultimately lead to a less expensive and quicker process compared to two separate submissions, says the analyst. He keeps a Buy rating on TG Therapeutics. $TGTX, TG Therapeutics, Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page